A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
48actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-04 | actual | When the study began enrolling |
| Primary completion | 2026-05-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-08 | actual | The whole study's end, after follow-up |
| First posted | 2025-12-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cardiac Repolarization
- Healthy Volunteers
Interventions
- Drug: Balinatunfib — also filed as SAR441566
- Drug: Moxifloxacin
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in the QT interval corrected using the Fridericia formula (QTcF) centrally assessed using a semi-automatic reading
measured Baseline to day 2
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed